- Acumen Powered by Robins Kaplan LLP™
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLPTM
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
October 21, 2021Oren Langer Named New York Managing Partner
-
October 19, 2021Three Robins Kaplan Partners Selected to Receive 2021 Minnesota Icon Award
-
October 18, 2021Women's Leadership Award Created in Memory of Hollis Salzman
-
October 25, 2021Women’s Bar Association of Massachusetts (WBA) 2021 Gala
-
October 28, 2021From Riches to Rags, a Story of a Damaged Nonprofit
-
October 29, 2021Eighth Circuit Judicial Conference
-
Fall 2021Are All Fiduciaries Created Equal?
-
Fall 2021Context Matters: Fiduciaries and the Rule Against Self-Dealing
-
Fall 2021Update on DOL Fiduciary Rule
-
October 20, 2021Financial Daily Dose 10.20.2021 | Top Story: Credit Suisse Fined $475M Over Mozambique Bribery Scandal
-
October 20, 2021The Robins Kaplan Privacy Pulse | Ransomware Attack Targets Sinclair Broadcast Group
-
October 19, 2021Financial Daily Dose 10.19.2021 | Top Story: SEC Issues Long-Awaited Report on Meme Stock Craze
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents
October 1, 2018
A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.
Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says
All Content © 2018, Portfolio Media, Inc.
Related Publications
July 15, 2021
Biotechnology & Trade Secret Protection
Sharon Roberg-Perez, David Prange, Ellen Levish - Bloomberg Law
June 8, 2021
Written Description in the Life Sciences: The Devil is in the Details
Sharon Roberg-Perez, William Jones - IPWatchdog
May 5, 2021
Bio-Rad Ruling Highlights IP Assignment Clause Limits
Bryan J. Vogel, Derrick J. Carman - Law360
March 26, 2021
Trends In Video Game Company Quests To Arbitrate Cases
Matthew Woods, Austin Miller - Law360
February 3, 2021
Navigating Software License Disputes in the Continuing Work-From-Home World
Bryan Mechell, Ellen Levish
Related News
September 20, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.